4.88 -0.24 (-4.72%)
MITI
Stock Details
Last Trade:4.88 Change:-0.24 (-4.72%) Prev Close:5.12 Open: 5.09 Days Range:4.75 – 5.09 52 Week Range: 2.25 - 7.74 Volume:273543 P/E: N/AEPS:-0.63
View AllRecent Alerts 07/04/09
Recent Alert on 06/18/09 at 9:35am
Morning Movers 6/18: PIR, NNI, SLM, NPBC, ARM, MITI Higher; SOA, IMGN, HPT, LIZ, CLC Lower
Morning Movers 6/18: PIR, NNI, SLM, NPBC, ARM, MITI Higher; SOA, IMGN, HPT, LIZ, CLC Lower
Pier 1 Imports, Inc. (NYSE: PIR) 18.6% HIGHER; reports Q1 EPS of $0.32, versus the analyst estimate of ($0.36) and compared to ($0.37) reported in the same quarter last year. Revenue for the quarter was $281.13 million, versus the consensus of... Read More
Recent Alert on 06/08/09 at 1:19pm
Unusual 11 Mid-Day Movers 6/8: ANPI, MFRI, RSOL, KERX Higher; XTNT, EMIS, AGEN, AIB Lower
Unusual 11 Mid-Day Movers 6/8: ANPI, MFRI, RSOL, KERX Higher; XTNT, EMIS, AGEN, AIB Lower
Recent Alert on 06/08/09 at 9:27am
Morning Movers 6/8: ANPI, MITI, KERX, DYAX, MSPD, MNKD Higher; AIB, LYG, XTNT, IRE Lower
Morning Movers 6/8: ANPI, MITI, KERX, DYAX, MSPD, MNKD Higher; AIB, LYG, XTNT, IRE Lower
Recent Alert on 06/08/09 at 9:09am
ANPI, STEM, CTIC, KERX, XOMA, MITI, MBRX See Volume and Upside Price Action
ANPI, STEM, CTIC, KERX, XOMA, MITI, MBRX See Volume and Upside Price Action
Recent Alert on 06/08/09 at 7:56am
Micromet (MITI) Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
Micromet (MITI) Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available